Citius Pharmaceuticals (NASDAQ:CTXR) Issues Earnings Results

Citius Pharmaceuticals (NASDAQ:CTXR) issued its quarterly earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01), Zacks reports.

Citius Pharmaceuticals Stock Down 5.0 %

Shares of NASDAQ CTXR traded down $0.03 during midday trading on Wednesday, hitting $0.58. The stock had a trading volume of 745,374 shares, compared to its average volume of 1,582,318. The company has a market capitalization of $104.79 million, a price-to-earnings ratio of -2.54 and a beta of 1.67. Citius Pharmaceuticals has a 1-year low of $0.48 and a 1-year high of $1.07. The company has a fifty day moving average price of $0.73 and a 200 day moving average price of $0.74.

Analysts Set New Price Targets

A number of analysts have issued reports on CTXR shares. EF Hutton Acquisition Co. I raised Citius Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 15th. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a research note on Friday, May 31st.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.